Polygenic risk scores in pharmacogenomics: opportunities and challenges—a mini review

• Published in: Frontiers in genetics Vol. 14; p. 1217049
• Main Authors: Simona, Aurélien, Song, Wenyu, Bates, David W., Samer, Caroline Flora
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 15.06.2023
• Subjects: adverse drug reaction (ADR); clinical decision support (CDS); functional genomic; Genetics; pharmacogenomics; polygenic risk score (PRS); precision medicine; precision medicine; functional genomic; pharmacogenomics; polygenic risk score (PRS); clinical decision support (CDS); adverse drug reaction (ADR)
• ISSN: 1664-8021; 1664-8021
• DOI: 10.3389/fgene.2023.1217049

Pharmacogenomics (PGx) aims at tailoring drug therapy by considering patient genetic makeup. While drug dosage guidelines have been extensively based on single gene mutations (single nucleotide polymorphisms) over the last decade, polygenic risk scores (PRS) have emerged in the past years as a promising tool to account for the complex interplay and polygenic nature of patients’ genetic predisposition affecting drug response. Even though PRS research has demonstrated convincing evidence in disease risk prediction, the clinical utility and its implementation in daily care has yet to be demonstrated, and pharmacogenomics is no exception; usual endpoints include drug efficacy or toxicity. Here, we review the general pipeline in PRS calculation, and we discuss some of the remaining barriers and challenges that must be undertaken to bring PRS research in PGx closer to patient care. Besides the need in following reporting guidelines and larger PGx patient cohorts, PRS integration will require close collaboration between bioinformatician, treating physicians and genetic consultants to ensure a transparent, generalizable, and trustful implementation of PRS results in real-world medical decisions.